The FDA has approved enlicitide, the first oral pill capable of lowering "bad" cholesterol by nearly 60 percent.
The Food and Drug Administration recently approved enlicitide, a daily tablet designed to significantly reduce low-density lipoprotein (LDL) cholesterol. This medication marks the first oral version of the PCSK9 inhibitor class, which previously required injections. Enlicitide offers a convenient alternative for patients who struggle with the muscle aches of traditional statins or those who are "needle shy." Clinical trials show that enlicitide lowers LDL by nearly 60 percent, performing similarly to powerful injectable drugs. While it is not expected to replace statins for every patient, it provides a vital option for those whose cholesterol remains high despite standard treatment. Experts note that the pill's lower price point and ease of use could make it a staple in primary care. However, doctors emphasize that patient adherence remains a key factor, as patients may forget to take a daily pill compared to a scheduled injection. Long-term studies are currently underway to confirm if the pill provides the same reduction in heart attacks and strokes as its injectable counterparts.